Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Folate, homocysteine and neural tube defects: an overview van der Put NM; van Straaten HW; Trijbels FJ; Blom HJExp Biol Med (Maywood) 2001[Apr]; 226 (4): 243-70Folate administration substantially reduces the risk on neural tube detects (NTD). The interest for studying a disturbed homocysteine (Hcy) metabolism in relation to NTD was raised by the observation of elevated blood Hcy levels in mothers of a NTD child. This observation resulted in the examination of enzymes involved in the folate-dependent Hcy metabolism. Thus far, this has led to the identification of the first and likely a second genetic risk factor for NTD. The C677T and A1298C mutations in the methylenetetrahydrofolate reductase (MTHFR) gene are associated with an increased risk of NTD and cause elevated Hcy concentrations. These levels can be normalized by additional folate intake. Thus, a dysfunctional MTHFR partly explains the observed elevated Hcy levels in women with NTD pregnancies and also, in part, the protective effect of folate on NTD. Although the MTHFR polymorphisms are only moderate risk factors, population-wide they may account for an important part of the observed NTD prevalence.|Animals[MESH]|Female[MESH]|Folic Acid/blood/chemistry/*metabolism/therapeutic use[MESH]|Homocysteine/blood/*metabolism[MESH]|Humans[MESH]|Infant, Newborn[MESH]|Intestinal Absorption[MESH]|Methylenetetrahydrofolate Reductase (NADPH2)[MESH]|Models, Chemical[MESH]|Neural Tube Defects/embryology/*genetics/prevention & control[MESH]|Oxidoreductases Acting on CH-NH Group Donors/deficiency/*genetics[MESH]|Pregnancy[MESH]|Prevalence[MESH] |
